RELAY+: Final Overall Survival With Ramucirumab Plus Gefitinib in Patients With Untreated EGFR-Mutated Metastatic NSCLC

By afschroeder • November 25, 2025

Nishio M, Seto T, Reck M, Garon EB, Nishio K, Kasahara K, Nishino K, Satouchi M, Yoh K, Hayashi H, Sakai K, Enatsu S, Matsui T, Varughese SC, Carlsen M, Visseren-Grul C, Nakagawa K. RELAY+: Final Overall Survival With Ramucirumab Plus Gefitinib in Patients With Untreated EGFR-Mutated Metastatic NSCLC. JTO Clin Res Rep. 2025 Sep 26;6(12):100912. doi: 10.1016/j.jtocrr.2025.100912. PMID: 41278399; PMCID: PMC12629876.

Tags: EGFR, Gefitinib, Hematology/Oncology, Non–small cell lung carcinoma, overall survival, Publications, ramucirumab

Secondary Neuropathy From Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal Gammopathy, and Skin Changes (POEMS) Syndrome: A Case Report

Young P, Kroloff M. Secondary Neuropathy From Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal Gammopathy, and Skin Changes (POEMS) Syndrome: A Case Report. Cureus. 2025 Oct 21;17(10):e95064. doi:[...]

Emerging Therapies for Sickle Cell Disease: From Symptom Management to Curative Gene Therapy

Duesberg MS, Schiller G. Emerging Therapies for Sickle Cell Disease: From Symptom Management to Curative Gene Therapy. Cureus. 2025 Oct 21;17(10):e95112. doi: 10.7759/cureus.95112. PMID: 41281092;[...]

HDAC4/MybL1/YAP novel signaling axis is required for pancreatic cancer metastasis to the liver

Edderkaoui M, Elmadbouh OHM, Lim A, Ou Y, Hauptschein D, Guha A, Darwish A, Calsavara VF, Murali R, Bhowmick N, Osipov A, Mathison AJ, Urrutia[...]